As American Merck (MSD) accelerates its plan to launch the cancer drug Keytruda in a subcutaneous injection (SC) formulation instead of an intravenous injection (IV), a patent dispute has erupted over ...

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...